Subscribe to Updates in Legal, Economic & Regulatory Affairs

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.




This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Study Group: Class Action Experts: Lawyers (US)(?)

Council Members in this Study Group: 47

This study group may include professors, attorneys, former regulatory officers, and consultants knowledgeable on topics such as law and litigation issues, lobbying, policy and government, elections, antitrust, immigration, intellectual property, and legislation, among others.

Request a survey with this Study Group







GLG NewsSMAnalyses by this Study Group's Experts(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
Will the card industry's survival of tight interchange fee caps in Australia similarly doom the fee in the US and EU? | 06-23-2008
Author: GLG Expert Contributor

The Lafferty study indicates that forced reductions of bankcard interchange fees in Australia have not significantly harmed issuer or network profits.  This is the exact opposite of what industry representatives had predicted.  If Lafferty is on target, interchange pricing...

The Financial Responsibility Rests with The Manufacturer | 03-14-2008
Analysis of: Heparin and other outsourced pharmaceuticals | online.wsj.com
Author: GLG Expert Contributor

The financial responsibity will lie with Baxter, not the FDA.  Perhaps moral or political responsibility (and fall out) will rest with the FDA, but that is of no help to those harmed by the Heparin.  Their only recourse is to sue the manufacturer.

The FDA has become a tool of politics rather than public safety | 03-14-2008
Analysis of: Court Allows Suit Against Drug Maker | www.nytimes.com
Author: GLG Expert Contributor

Under the current administration, the FDA has tried to use drug approval as a shield.  In some cases, the current court has held warning approval to bar lawsuits.  However, this can be remedied by Congress explicitly clarifying that the FDA approval of a drug does not preempt state law....

Prognosis for Visa's coming IPO | 03-11-2008
Analysis of: Rocky Road for Visa's IPO |
Author: GLG Expert Contributor

Investors, including bankcard issuers, want the Visa IPO to be at least as successful as MasterCard's in '06. Visa's global legal problems, which are especially acute in the US and EU, could burden Visa far into the future. The US credit crunch could hold surprises for Visa, more so if Democrats...

Benefits of mortgage meltdown to bankcard industry | 11-30-2007
Author: GLG Expert Contributor

To prevent the mortgage meltdown from spreading to payment cards, Congress will suspend aggressive reforms against bankcard lenders and other government pressure (from the feds and perhaps the DoJ) will help to minimize their risks in the interchange antitrust lawsuits.  Thus what Paulson...

View All GLG News by members of this Study Group

Most Common Company Types:

  • Law Firm (general practice/large)
  • Law Firm (Boutique / Specialized)
  • Law firm (small / solo)
  • Academic Institution*
  • Individual Attorney

Most Common Job Types:

  • Partner
  • Attorney
  • Principal

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics